A turn of the shovel has formally launched the transformation at the future home of more than 800 CSL employees and leading-edge biotechnology laboratories in Melbourne, Australia.
The first phase of construction of CSL’s new corporate headquarters officially got underway this month with a ground breaking ceremony. CSL was represented at the event by Chief Scientific Officer & CSL Limited Executive Director Andrew Cuthbertson, who said the new facility “will play an important role in the translation of benchtop research to new breakthrough medicines.”
The planned 16-story flagship building in the Parkville precinct will include both lab space and clinical production suites. The strategic location puts CSL researchers close to leading medical and research institutions, including the University of Melbourne, the Walter and Eliza Hall Institute of Medical Research and several hospitals that all call Parkville home.
“As the country’s largest private investor in biomedical research, collaboration with the biomedical research community is extremely important to CSL,” Cuthbertson said. “We want to be here, shoulder-to-shoulder with our colleagues at the University of Melbourne, the medical research institutes and the hospitals, because it is the people and the personal relationships that will make this precinct even more than the sum of its parts.”
The new space is due for completion in 2023 with the entire CSL headquarters finished by 2024. For more information on CSL’s future headquarters, click here.
